Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It is used to prevent cerebral vasospasm following subarachnoid hemorrhage in patients at risk of ischemic complications.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimotop is a calcium channel blocker indicated for the management of cerebrovascular complications after subarachnoid hemorrhage.

- Subarachnoid hemorrhage (post‑SAH): Prevention of cerebral vasospasm and associated ischemic injury.

Nimotop may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient blood‑pressure reduction. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation and reddening of skin. - Dizziness: sensation of light‑headedness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reaction: rash, itching, or swelling. - Neutropenia: reduced white‑blood‑cell count. - Seizures: rare occurrence of convulsive episodes.

Before initiating Nimotop, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Blood pressure monitoring: check for hypotension during therapy. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy: prescribe only if potential benefit outweighs risk. - Elderly patients: start at lower dose and titrate cautiously. - Store at below 25°C: keep in the original pack, protect from moisture.

Nimotop can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nimodipine plasma levels. - Other calcium channel blockers: additive vasodilatory effect leading to hypotension. - Nitrates: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Beta‑blockers: combined effect on heart rate and blood pressure. - Diuretics: may enhance orthostatic hypotension.